Skip to content

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

Evaluating the HITSystem to Improve PMTCT Retention and Maternal Viral Suppression in Kenya

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04571684
Enrollment
1639
Registered
2020-10-01
Start date
2020-10-05
Completion date
2024-04-01
Last updated
2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV, Pregnancy

Keywords

Prevention of mother-to-child transmission (PMTCT) services, maternal viral load monitoring, early infant diagnosis (EID), Kenya, perinatal HIV transmission

Brief summary

The goal of this project is to rigorously evaluate the efficacy of HIV Infant Tracking System 2.1 (HITSystem, an eHealth intervention that uses short message service (SMS) texts to patients and algorithm-driven electronic alerts for providers) to increase retention in guideline-adherent prevention of mother-to-child transmission of HIV services (PMTCT) and to increase viral suppression and appropriate clinical action through the extended period of 6 months postpartum, compared to standard of care PMTCT services in a matched, cluster randomized controlled trial.

Detailed description

Despite progress in providing comprehensive prevention of mother-to-child transmission of HIV (PMTCT) services, significant gaps in the timely uptake and provision of guideline-adherent services and maternal retention in care remain. Such gaps create missed opportunities for preventing mother-to-child transmission and result in nearly 6,100 infants becoming infected with HIV each year in Kenya. Effective interventions that routinize the delivery of evidence-based PMTCT services and foster consistent patient engagement are essential to close the remaining gaps and eliminate mother-to-child transmission of HIV. Building off of a successful R34 grant to develop and pilot test the HITSystem 2.0, an eHealth intervention targeting PMTCT services, the overall goal of this proposal is to use a cluster randomized control design at 12 Kenyan government hospitals to evaluate a modified HITSystem 2.1 intervention. HITSystem 2.1 reflects the 2018 Kenyan PMTCT guidelines, including routine viral load monitoring and interventions to suppress maternal viral load. The investigators aim to evaluate the impact of HITSystem 2.1 to optimize the provision of guideline-adherent services and viral suppression through the antenatal, delivery, and early postpartum periods. Aim 1 of the proposed study will assess the efficacy of the HITSystem 2.1 to increase the proportion of mothers who receive complete PMTCT services (including appointment attendance, medication adherence support, viral load testing, hospital-based delivery, and infant testing per Kenyan National Guidelines) through 6 months postpartum. The investigators hypothesize that mothers receiving the HITSystem 2.1 intervention will have a significantly higher completion rate for guideline-adherence PMTCT services compared to mothers receiving standard of care PMTCT services. In Aim 1b, the investigators will evaluate HITSystem 2.1 implementation using the RE-AIM model to inform sustainable scale up. Aim 2 will assess the efficacy of HITSystem 2.1 to increase viral suppression (\<1,000 copies/mL) among pregnant and postpartum women, including those who disengage from care. The investigators hypothesize that mothers at HITSystem 2.1 sites will have higher rates of viral suppression at delivery and 6 months postpartum. Aim 3 will evaluate the cost-effectiveness of the HITSystem 2.1. Driven by differences in PMTCT retention, viral suppression, and modeled estimates of pediatric HIV infections averted, the investigators hypothesize that the HITSystem 2.1 will be cost-effective, based on World Health Organization criteria. This proposal is aimed at improving the quality of PMTCT services in the health facility setting. If efficacious and cost-effective, HITSystem 2.1 holds strong promise for national dissemination.

Interventions

OTHERHITSystem 2.1

HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.

Sponsors

Kenya Medical Research Institute
CollaboratorOTHER
Children's Mercy Hospital Kansas City
CollaboratorOTHER
Global Health Innovations Foundation - Kenya
CollaboratorUNKNOWN
National Institute of Mental Health (NIMH)
CollaboratorNIH
University of Kansas Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Matched, cluster randomized controlled design

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Pregnant women living with HIV who present for care at one of the study hospitals by 36 weeks gestation and provide written informed consent are eligible for enrollment in the study.

Exclusion criteria

* Pregnant women living with HIV will be excluded from study participation if she has any condition (including drug abuse, alcohol abuse, or psychiatric disorder) that study or hospital staff feel precludes her from providing informed consent. * Women who transfer care from one study site to another during their PMTCT services will be ineligible for enrollment at their new facility.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Receiving Complete PMTCT7-15 months (PMTCT enrollment date through 6 months postpartum)documented receipt of all of the following: maternal ART initiation, antenatal appointment attendance, facility delivery, EID linkage by 7 weeks of age, maternal viral load testing and clinical action per national guidelines through 6 months postpartum (Table 6). Participants who receive all indicated services per guidelines will be coded as 1 or 'yes'. Participants missing \> 1 service will be coded as 0 or incomplete PMTCT services.
Viral Suppression1-9 monthsNumber of clients with a suppressed viral load(\<1000 copies/mL) at delivery

Secondary

MeasureTime frameDescription
PMTCT Retention Duration (Weeks)7-15 months (PMTCT enrollment date through 6 months postpartum)The number of weeks women were engaged in PMTCT services
Antenatal Viral Load (VL) Test CoverageWithin one month of enrollment in PMTCTThe number of women receiving viral load testing upon enrolling in prevention of mother to child transmission of HIV services (PMTCT).
Turnaround Time of Viral Load Sample Collection to Patient NotificationPMTCT enrollment date through 6 months postpartumThe median number of days from the date of VL sample collection to patient notification, among all viral load tests
Viral Load Test UtilityPMTCT enrollment date through 6 months postpartumNumber of detectable viral load results with clinical action per guidelines, such as: intensified adherence counseling and/or ARV regimen change
Postnatal Viral Load (VL) Test CoverageBetween delivery and 7 months postpartumThe number of women receiving postpartum viral load testing per the Kenyan national guidelines.
Antiretroviral Therapy (ART) Adherence7-15 months (PMTCT enrollment date through 6 months postpartum)The number of participants with ART adherence \> 95%

Countries

Kenya

Participant flow

Participants by arm

ArmCount
Intervention Arm (HITSystem 2.1)
Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed. HITSystem 2.1: HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
767
Control Arm (Standard of Care)
Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up.
627
Total1,394

Baseline characteristics

CharacteristicControl Arm (Standard of Care)Intervention Arm (HITSystem 2.1)Total
Age, Continuous30.4 years
STANDARD_DEVIATION 6
30.6 years
STANDARD_DEVIATION 5.8
30.5 years
STANDARD_DEVIATION 5.9
Education level
Beyond secondary education
41 Participants43 Participants84 Participants
Education level
Completed secondary education
74 Participants112 Participants186 Participants
Education level
Less than secondary education
508 Participants611 Participants1119 Participants
Education level
Missing
4 Participants1 Participants5 Participants
Gestational week at enrollment19.9 weeks
STANDARD_DEVIATION 7.3
19.1 weeks
STANDARD_DEVIATION 7.8
19.5 weeks
STANDARD_DEVIATION 7.6
HIV disclosure
Anyone
535 Participants676 Participants1211 Participants
HIV disclosure
Missing
3 Participants1 Participants4 Participants
HIV disclosure
No one
89 Participants90 Participants179 Participants
Household income
<750 KSh
224 Participants268 Participants492 Participants
Household income
>=750 KSH
257 Participants336 Participants593 Participants
Household income
Missing
146 Participants163 Participants309 Participants
Partner living situation
Live separate from partner
104 Participants128 Participants232 Participants
Partner living situation
Live with current partner
459 Participants581 Participants1040 Participants
Partner living situation
Missing
6 Participants6 Participants12 Participants
Partner living situation
No current partner
58 Participants52 Participants110 Participants
Past experience with prevention of mother to child transmission(PMTCT)/early infant diagnosis (EID)
No
272 Participants290 Participants562 Participants
Past experience with prevention of mother to child transmission(PMTCT)/early infant diagnosis (EID)
Yes
355 Participants477 Participants832 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Kenya
627 participants767 participants1394 participants
Sex: Female, Male
Female
627 Participants767 Participants1394 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Time of antiretroviral treatment (ART) initiation
>5 years prior to current pregnancy
232 Participants274 Participants506 Participants
Time of antiretroviral treatment (ART) initiation
<5 yrs prior to current pregnancy
228 Participants331 Participants559 Participants
Time of antiretroviral treatment (ART) initiation
During current pregnancy
145 Participants162 Participants307 Participants
Time of antiretroviral treatment (ART) initiation
Missing
22 Participants0 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
14 / 89922 / 740
other
Total, other adverse events
0 / 8990 / 740
serious
Total, serious adverse events
41 / 89941 / 740

Outcome results

Primary

Number of Participants Receiving Complete PMTCT

documented receipt of all of the following: maternal ART initiation, antenatal appointment attendance, facility delivery, EID linkage by 7 weeks of age, maternal viral load testing and clinical action per national guidelines through 6 months postpartum (Table 6). Participants who receive all indicated services per guidelines will be coded as 1 or 'yes'. Participants missing \> 1 service will be coded as 0 or incomplete PMTCT services.

Time frame: 7-15 months (PMTCT enrollment date through 6 months postpartum)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Arm (HITSystem 2.1)Number of Participants Receiving Complete PMTCT60 Participants
Control Arm (Standard of Care)Number of Participants Receiving Complete PMTCT22 Participants
Primary

Viral Suppression

Number of clients with a suppressed viral load(\<1000 copies/mL) at delivery

Time frame: 1-9 months

Population: The overall number of participants analyzed include only those who had a documented viral load test at delivery.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Arm (HITSystem 2.1)Viral Suppression655 Participants
Control Arm (Standard of Care)Viral Suppression535 Participants
Secondary

Antenatal Viral Load (VL) Test Coverage

The number of women receiving viral load testing upon enrolling in prevention of mother to child transmission of HIV services (PMTCT).

Time frame: Within one month of enrollment in PMTCT

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Arm (HITSystem 2.1)Antenatal Viral Load (VL) Test Coverage330 Participants
Control Arm (Standard of Care)Antenatal Viral Load (VL) Test Coverage137 Participants
Secondary

Antiretroviral Therapy (ART) Adherence

The number of participants with ART adherence \> 95%

Time frame: 7-15 months (PMTCT enrollment date through 6 months postpartum)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Arm (HITSystem 2.1)Antiretroviral Therapy (ART) Adherence466 Participants
Control Arm (Standard of Care)Antiretroviral Therapy (ART) Adherence200 Participants
Secondary

PMTCT Retention Duration (Weeks)

The number of weeks women were engaged in PMTCT services

Time frame: 7-15 months (PMTCT enrollment date through 6 months postpartum)

ArmMeasureValue (MEAN)Dispersion
Intervention Arm (HITSystem 2.1)PMTCT Retention Duration (Weeks)48.4 weeksStandard Deviation 9.6
Control Arm (Standard of Care)PMTCT Retention Duration (Weeks)47.2 weeksStandard Deviation 8.1
Secondary

Postnatal Viral Load (VL) Test Coverage

The number of women receiving postpartum viral load testing per the Kenyan national guidelines.

Time frame: Between delivery and 7 months postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Arm (HITSystem 2.1)Postnatal Viral Load (VL) Test Coverage518 Participants
Control Arm (Standard of Care)Postnatal Viral Load (VL) Test Coverage371 Participants
Secondary

Turnaround Time of Viral Load Sample Collection to Patient Notification

The median number of days from the date of VL sample collection to patient notification, among all viral load tests

Time frame: PMTCT enrollment date through 6 months postpartum

Population: Turnaround time was measured among all viral load samples taken in the antenatal and/or postpartum periods.

ArmMeasureValue (MEDIAN)
Intervention Arm (HITSystem 2.1)Turnaround Time of Viral Load Sample Collection to Patient Notification35 days
Control Arm (Standard of Care)Turnaround Time of Viral Load Sample Collection to Patient Notification35 days
Secondary

Viral Load Test Utility

Number of detectable viral load results with clinical action per guidelines, such as: intensified adherence counseling and/or ARV regimen change

Time frame: PMTCT enrollment date through 6 months postpartum

Population: Viral load test utility was analyzed only among those participants with a detectable viral load result.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Arm (HITSystem 2.1)Viral Load Test Utility28 Participants
Control Arm (Standard of Care)Viral Load Test Utility18 Participants

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026